Harris Beach Murtha Partner Kelly Jones Howell’s opinion article on a U.S. Supreme Court decision strengthening preemption defenses for FDA-regulated products recently appeared in amNY Law.
Kelly, leader of the firm’s Medical and Life Sciences Practice Group, discussed the 7-2 ruling in Monsanto Co. v. Durnell that came after decades of glyphosate litigation. Glyphosate is the active herbicide in Monsanto’s Roundup weedkiller.
Despite the World Health Organization’s International Agency for Research on Cancer classifying glyphosate as “probably carcinogenic” – a move that led to thousands of lawsuits producing billions in damages against Monsanto and Roundup – the U.S. Environmental Protection Agency (EPA) has conducted its own research and repeatedly ruled Roundup and similar herbicides do not need to carry a cancer warning. Despite the EPA determination, some courts have attempted to force the cancer-warning labels on to the herbicides.
The Supreme Court ruled such lawsuits are barred because the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) authorizes the EPA to regulate the use, sale and labeling of pesticides and it includes a requirement prohibiting states from imposing additional labeling requirements.
“While this is a major victory for Monsanto, it should also be viewed as a win for medical device and over-the-counter drug manufacturers that market products regulated by federal agencies, as the Supreme Court ruling holds that preemption clauses found in statutes governing federal agencies bar states from adding additional regulatory requirements,” Kelly wrote.
Harris Beach Murtha writes monthly opinion pieces for the publication. You can read Kelly’s full article here.